ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Aticaprant

Also written as “JNJ-67953964”, “14C-aticaprant” and “Aticaprant Supratherapeutic Dose”.

Its studies are mostly in Depressive Disorder, Major · Schizophrenia · Smoking · Alcoholism, led by 2 companies.

Drug pageAticaprant: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 10, 202213 company-led studies, 1 open or runningNext primary completion: Jun 21, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only121 open or runningphase 3since Jul 10, 2022Dec 15, 2015Jun 21, 2027phase 1 · NCT07615426
Eli Lillyits history only10 open or runningphase 1since Oct 20, 2010Oct 20, 2010none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 20, 2010First study: phase 1 study in AlcoholismNew to Eli LillyEli Lilly · NCT01232439 · 13 enrolled · United States
  2. Dec 15, 2015Johnson & Johnson’s first study: phase 2 study in SmokingNew to Johnson & JohnsonJohnson & Johnson · NCT02641028 · 71 enrolled · United States
  3. Jun 6, 2018Phase 2 study in Depressive Disorder, MajorJohnson & Johnson · NCT03559192 · 181 enrolled · United States, Germany, Moldova, Republic of and more
  4. Jun 9, 2018Named aticaprantINNProposed as its International Nonproprietary Name in WHO's List 119 · before, JNJ-67953964
  5. Dec 2, 2019Phase 1 study in HealthyJohnson & Johnson · NCT04185051 · 76 enrolled · Belgium
  6. Mar 9, 2021Phase 1 study in HealthyJohnson & Johnson · NCT04791332 · 30 enrolled · Japan
  7. Jan 17, 2022Phase 1 study in HealthyJohnson & Johnson · NCT05197062 · 8 enrolled · Netherlands
  8. May 20, 2022Phase 1 study in HealthyJohnson & Johnson · NCT05387759 · 60 enrolled · Belgium
  9. Jul 10, 2022Phase 3 study in Depressive Disorder, MajorJohnson & Johnson · NCT05455684 · 513 enrolled · United States, Argentina, Australia and more
  10. Aug 25, 2022Phase 3 study in Depressive Disorder, MajorJohnson & Johnson · NCT05518149 · 871 enrolled · United States, Argentina, Australia and more
  11. Sep 20, 2022Phase 3 study in Depressive Disorder, MajorJohnson & Johnson · NCT05550532 · 444 enrolled · United States, Argentina, Brazil and more
  12. Jul 17, 2024Phase 3 study in Depressive Disorder, MajorJohnson & Johnson · NCT06514742 · 101 enrolled · United States, Belgium, Brazil and more
  13. Oct 9, 2024Phase 3 study in Depressive Disorder, MajorJohnson & Johnson · NCT06635135 · 47 enrolled · United States, Argentina, Belgium and more
  14. May 22, 2026Phase 1 study in SchizophreniaJohnson & Johnson · NCT07615426 · 64 planned · United States

Ahead

  1. Jun 21, 2027Primary completion: phase 1 study in SchizophreniaJohnson & Johnson · NCT07615426

TargetBeta

OPRK1 →read by rule
“Kappa opioid receptor antagonist”ChEMBL 37, by rule

Other programs on OPRK1

ProgramCompanyFurthest phaseStudies
Naltrexoneruleorexigen-therapeutics-incphase 442
NalbuphineruleTrevi Therapeuticsphase 421
nalmefeneruleH. Lundbeckphase 420
cebranopadolruleTris Pharmaphase 318
nalfurafineruletoray-industries-incphase 39
asimadolineruletioga-pharmaceuticalsphase 36
icalcaprantAbbViephase 26

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07615426Schizophrenia · United States1RecruitingJohnson & JohnsonJun 21, 202764
NCT06635135Depressive Disorder, Major · United States, Argentina, Belgium and more3TerminatedJohnson & JohnsonApr 9, 202547
NCT06514742Depressive Disorder, Major · United States, Belgium, Brazil and more3TerminatedJohnson & JohnsonApr 8, 2025101
NCT05550532Depressive Disorder, Major · United States, Argentina, Brazil and more3CompletedJohnson & JohnsonNov 8, 2024444
NCT05518149Depressive Disorder, Major · United States, Argentina, Australia and more3TerminatedJohnson & JohnsonApr 25, 2025871
NCT05455684Depressive Disorder, Major · United States, Argentina, Australia and more3CompletedJohnson & JohnsonSep 18, 2024513
NCT05387759Healthy · Belgium1CompletedJohnson & JohnsonOct 4, 202260
NCT05197062Healthy · Netherlands1CompletedJohnson & JohnsonMar 2, 20228
NCT04791332Healthy · Japan1CompletedJohnson & JohnsonJul 28, 202130
NCT04185051Healthy · Belgium1CompletedJohnson & JohnsonApr 21, 202176
NCT03559192Depressive Disorder, Major · United States, Germany, Moldova, Republic of and more2CompletedJohnson & JohnsonMay 6, 2020181
NCT02641028Smoking · United States2CompletedJohnson & JohnsonSep 13, 201671
NCT01232439Alcoholism · United States1CompletedEli LillyApr 201113

How it is read

Names in the registry

  • “Aticaprant”, 6 entries
  • “JNJ-67953964”, 3 entries
  • “14C-aticaprant”, 1 entry
  • “Aticaprant Supratherapeutic Dose”, 1 entry
  • “Aticaprant Therapeutic Dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.